By Colin Kellaher
Boston Scientific has agreed to buy the rest of privately held medical-device company SoniVie for an initial $360 million in a deal that expands its portfolio of interventional cardiology therapies.
Boston Scientific, which already owns 10% of SoniVie, said it could pay up to an additional $180 million upon achievement of a regulatory milestone.
SoniVie has developed the investigational Tivus intravascular ultrasound system, designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation for hypertension, Boston Scientific said.
The Marlborough, Mass., medical-technology company said it expects to complete the acquisition in the first half of 2025.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 03, 2025 07:20 ET (12:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。